Plain-English translation of NCT06893133 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is testing a blood test called ctDNA-MRD (circulating tumor DNA minimal residual disease) that can detect tiny amounts of cancer cells remaining in your body after gastric cancer surgery and chemotherapy. The blood test is much more sensitive than traditional imaging scans and may catch cancer recurrence months earlier, when tumors are smaller and potentially easier to treat.
Currently, doctors use CT scans and other imaging to watch for cancer coming back after surgery, but these methods can only see tumors once they've grown to a certain size. This study exists because the new blood test could find cancer recurrence much earlier—sometimes months before imaging shows anything—giving doctors a chance to intervene when treatment might be more effective.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn at multiple time points after your surgery to test for remaining cancer cells using the new blood test. You will also continue standard follow-up care, including imaging scans and endoscopy as recommended by your doctor. The study will compare how well the blood test detects cancer recurrence compared to traditional imaging methods, and researchers will track your health over time to see if the blood test can predict recurrence earlier.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China